BETA BIONICS INC (BBNX) Stock Price, Quote, News and Overview
NASDAQ:BBNX - Nasdaq - US08659B1026 - Common Stock - Currency: USD
BBNX Quote, Performance and Key Statistics
10.96
-0.1 (-0.9%)
The current stock price of BBNX is 10.96 USD. In the past month the price decreased by -13.5%.
BBNX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.96 | 223.47B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.35 | 184.36B | ||
| BSX | BOSTON SCIENTIFIC CORP | 37.74 | 150.72B | ||
| SYK | STRYKER CORP | 29.95 | 139.34B | ||
| MDT | MEDTRONIC PLC | 15.76 | 107.94B | ||
| BDX | BECTON DICKINSON AND CO | 14.74 | 58.89B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.25 | 44.70B | ||
| IDXX | IDEXX LABORATORIES INC | 38.88 | 35.45B | ||
| RMD | RESMED INC | 25.98 | 34.64B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.24 | 31.33B | ||
| DXCM | DEXCOM INC | 43.43 | 28.10B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 15.94 | 23.53B |
Related stock screener links
About BBNX
Company Profile
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 291 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
Company Info
BETA BIONICS INC
11 Hughes
Irvine CALIFORNIA US
Employees: 291
Company Website: https://www.betabionics.com
Investor Relations: http://www.betabionics.com/about-us/investors/
Phone: 19494277785
BETA BIONICS INC / BBNX FAQ
What is the stock price of BETA BIONICS INC today?
The current stock price of BBNX is 10.96 USD. The price decreased by -0.9% in the last trading session.
What is the ticker symbol for BETA BIONICS INC stock?
The exchange symbol of BETA BIONICS INC is BBNX and it is listed on the Nasdaq exchange.
On which exchange is BBNX stock listed?
BBNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BETA BIONICS INC stock?
13 analysts have analysed BBNX and the average price target is 26.23 USD. This implies a price increase of 139.31% is expected in the next year compared to the current price of 10.96. Check the BETA BIONICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BETA BIONICS INC worth?
BETA BIONICS INC (BBNX) has a market capitalization of 475.12M USD. This makes BBNX a Small Cap stock.
How many employees does BETA BIONICS INC have?
BETA BIONICS INC (BBNX) currently has 291 employees.
What are the support and resistance levels for BETA BIONICS INC (BBNX) stock?
BETA BIONICS INC (BBNX) has a support level at 10.22 and a resistance level at 11.15. Check the full technical report for a detailed analysis of BBNX support and resistance levels.
Is BETA BIONICS INC (BBNX) expected to grow?
The Revenue of BETA BIONICS INC (BBNX) is expected to grow by 27.44% in the next year. Check the estimates tab for more information on the BBNX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BETA BIONICS INC (BBNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BBNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BBNX, evaluating the profitability, health, valuation and growth aspects
- BETA BIONICS INC (BBNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BETA BIONICS INC (BBNX) Sales and EPS estimates to see what analysts future expectations are.
- BETA BIONICS INC (BBNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BETA BIONICS INC (BBNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BETA BIONICS INC (BBNX) Stock Chart to make your own analysis
- BETA BIONICS INC (BBNX) Latest news and press-releases to stay up to date.
Does BETA BIONICS INC (BBNX) stock pay dividends?
BBNX does not pay a dividend.
When does BETA BIONICS INC (BBNX) report earnings?
BETA BIONICS INC (BBNX) will report earnings on 2025-05-06.
What is the Price/Earnings (PE) ratio of BETA BIONICS INC (BBNX)?
BETA BIONICS INC (BBNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is the Short Interest ratio of BETA BIONICS INC (BBNX) stock?
The outstanding short interest for BETA BIONICS INC (BBNX) is 7.74% of its float. Check the ownership tab for more information on the BBNX short interest.
BBNX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BBNX.
BBNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BBNX. BBNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BBNX Financial Highlights
Over the last trailing twelve months BBNX reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -24.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.59% | ||
| ROE | -72.04% | ||
| Debt/Equity | 0 |
BBNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to BBNX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 11.87% and a revenue growth 27.44% for BBNX